EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Corvus Pharmaceuticals's enterprise value is $46.80 Mil.
Corvus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Corvus Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for Corvus Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
CRVS's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.68 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Corvus Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Corvus Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's EV-to-Revenue falls into.
Corvus Pharmaceuticals's current Enterprise Value is $46.80 Mil.
Corvus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals's share price for today is $1.44.
Corvus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Corvus Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRVS has been successfully added to your 